1. Is Immunomodulatory Property of Hydroxychloroquine Beneficial for Severe COVID-19? A Hospital Based Retrospective Observational Study
- Author
-
Debabrata Behera, Saroj Badapanda, Prasant Kumar Mishra, Mahesh Prasad Mohanta, Siddhartha Satapathy, Lavina Patnaik, Gayathri Prakash, and Deben Das
- Subjects
Pediatrics ,medicine.medical_specialty ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,business.industry ,QH301-705.5 ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Low dose ,Retrospective cohort study ,Hydroxychloroquine ,General Medicine ,Hospital based ,Disease ,hydroxychloroquine, hcq, covid-19, sars-cov-2 ,medicine ,Medicine ,Biology (General) ,business ,medicine.drug - Abstract
Since the beginning of the COVID-19 pandemic, Hydroxychloroquine is being prescribed by the doctors all over the world for the treatment as well as prevention of COVID-19 with varying results. As we know damage in severe COVID-19 disease occurs mainly via the immunological mechanism. There is an assumption that HCQ has immunomodulatory property and thus may have a beneficial role in severe COVID-19 disease. In this retrospective study, we describe our experience of using low dose of HCQ (200mg/day) in 27 hospitalized severe cases of COVID-19 disease. We found, though the use of HCQ resulted in improvements in chest X-rays, there was no significant reduction in the deaths in the cases where HCQ was used.
- Published
- 2021